Special Issue

Biological and Pharmacological Research on Indole-3-Carbinol (I3C) and Its Derivatives

Message from the Guest Editor

Indole-3-carbinol (I3C) is a natural compound found in vegetables from the Brassicaceae family. It has been extensively studied for its biological and pharmacological properties, including it ability to suppress cell cycle progression, block cancer cell migration, promote apoptosis, and inhibit tumor growth and Sars-CoV-2 viral egression. One of the main focuses for researchers is to make changes to I3C's chemical structure characteristics to improve its stability. Different design strategies were applied to enhance the possibility of performing lead optimization and obtaining derivatives with a better pharmacodynamic and pharmacokinetic profile than I3C. This Special Issue aims to invite both reviews and original articles that shed light on the biosynthetic processes and synthetic procedures for obtaining I3C and its main derivatives. This Special Issue's objective is also to explore the characteristics, mechanism of action, and therapeutic potential of I3C and/or its derivatives both in health and in preventing and treating various diseases.

Guest Editor

Dr. Federica Centofanti

Department of Biomedicine and Prevention—Medical Genetic Section, Tor Vergata University of Rome, 00133 Rome, Italy

Deadline for manuscript submissions

20 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/209218

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

